Added to YB: 2026-01-27
Pitch date: 2026-01-24
KZIA [neutral]
Kazia Therapeutics Limited
-16.76%
current return
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel.
Market Cap
$77.3M
Pitch Price
$7.52
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.52
P/E
-0.38
EV/Sales
40.08
Sector
Biotechnology
Category
N/A
Four Biotechs I’m Watching After the JPM Healthcare Conference - Kazia Therapeutics Limited
KZIA (watchlist): Australian biotech w/ brain-penetrant PI3K/mTOR inhibitor paxalisib for glioblastoma (>85% have overactive pathway). Phase 1b readout Jan 31, 2026. $80M mcap, high unmet need market. Key risks: early stage, limited patients, safety signals. Even modest activity significant in this lethal cancer.
Read full article (2 min)